Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03929783 · ClinicalTrials.gov registry record · NA
Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings
A NA study of Breast Neoplasms, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- NA
- Development phase
- 107
- Enrollment target
- 1
- Study location
NCT03929783: Completed NA study of Breast Neoplasms, sponsored by Thomas Jefferson University.
NCT03929783 is a NA study of Breast Neoplasms that has completed, run by Thomas Jefferson University. The registered enrollment target is 107 participants, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03929783, a NA study of Breast Neoplasms, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- NA
- Development phase
- 107 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot trial studies how well contrast enhanced mammography works in diagnosing patients with suspicious breast findings. Diagnostic procedures, such as contrast enhanced mammography, may help to reclassify findings seen on diagnostic mammography and ultrasound as benign or likely benign with what would otherwise require biopsy for confirmation.
Primary Outcome
The total number of suspicious and benign lesions on each modality (mammogram+ultrasound \[MM+US\] and CEM) will be calculated and compared to a final tissue diagnosis independently.
Conditions Studied
Interventions
- PROCEDURE Contrast Enhanced Digital Mammography
Study Locations (1)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2020-06-23 |
| Est. Completion | 2023-01-27 |
| Phase | NA |
What the finished NCT03929783 record still lists
NCT03929783 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Contrast Enhanced Digital Mammography is the first listed.
NCT03929783 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03929783 about?
NCT03929783 is a clinical study titled "Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings". This pilot trial studies how well contrast enhanced mammography works in diagnosing patients with suspicious breast findings. Diagnostic procedures, such as contrast enhanced mammography, may help to reclassify findings seen on diagnostic mammography and ultrasound as benign or likely benign with wh...
What is the current status of trial NCT03929783?
This trial is currently completed. It is a NA study. The enrollment target is 107 participants. The study started on 2020-06-23. Estimated completion is 2023-01-27.
What conditions does trial NCT03929783 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT03929783?
The interventions under investigation include: Contrast Enhanced Digital Mammography (PROCEDURE).
Who is sponsoring clinical trial NCT03929783?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03929783 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03929783's enrollment target sits among peer trials
107 53rd of 97 higher than 45 of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Breast Cancer, Reasoning, and Activity Intervention
RECRUITING · NA
-
Biennial CEM in Women With a Personal History of Breast Cancer
RECRUITING · NA
-
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
RECRUITING · NA
-
Dissemination of BREASTChoice AIM1-B
RECRUITING · NA
-
The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)
ACTIVE NOT RECRUITING · NA
-
Lifestyle, Exercise, and Nutrition Study Early After Diagnosis
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI